IDWeek 2024: The Impact and Potential of mRNA Medicines For Infectious Disease

Today is the start of IDWeek 2024, one of the leading infectious disease conferences in the world. Every year, Moderna looks forward to several days of learning, engaging with infectious disease scientists and experts, and collaborating with leaders in the infectious disease field.

Moderna’s Presentations at IDWeek 2024

2024 has been an important year for Moderna’s infectious disease portfolio, with the global launch of our RSV vaccine, mRESVIA, and worldwide approvals of our updated COVID-19 vaccines. In addition, we recently announced a significant milestone for our Norovirus vaccine candidate; just a couple of weeks ago, the first patient was dosed in our Phase 3 trial for the vaccine. At ID Week, Moderna will be presenting nine poster presentations highlighting research across our respiratory disease portfolio, as well as insights pertaining to norovirus and cytomegalovirus. In addition, Moderna will deliver the following oral presentations:

• Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to <18 Years at High Risk of Severe Disease
  Thursday, October 17, 1:45–3:00 PM, Room 403A
  Sabine Schnyder Ghamloush, Senior Director, Clinical Development, Infectious Disease, Moderna

• Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial
  Saturday, October 19, 1:45–3:00 PM Room 403A
  Till Schoofs, Director, Translational Medicine, Infectious Disease Development, Moderna

Sparking Important Conversations At The Conference

In addition to sharing our research, Moderna will host four presentation theater and Learning Lounge events, which will provide meaningful insights on mRNA-based respiratory vaccines and the potential of mRNA science:

• Navigating the Evolving Landscape of Respiratory Viruses: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States and the Role of the ID Specialist
  Tuesday, October 15th, 5:30 – 6:30 PM, JW Marriott Platinum Ballroom I-J
  L.J. Tan, MS, PhD, Chief Policy and Partnerships Officer at Immunize.org, Co-Chair of the National Adult and Influenza Immunization Summit
  Todd H. Wolynn, MD, President, Kids Plus Pediatrics, Executive Director, Breastfeeding Center of Pittsburg
  Dial Hewlett Jr, MD, Vice Chair, Westchester County Department of Health
  Leading experts will discuss methodologies and best practices for improving respiratory vaccine uptake.

• mRNA Science: This Changes Everything
  Thursday, October 17th, 11:15 – 12:00 PM, Learning Lounge 5
  Melissa Moore, PhD, Chief Scientific Officer, Emerita, Moderna, Galit Alter, PhD, Vice President, Immunology Research, Moderna, and Ann Falsey, MD, Professor of Medicine, University of Rochester School of Medicine, will share the history of mRNA science, its potential for the future, and the immunology and clinical significance of mRNA vaccines.

• COVID-19 Vaccination Today: Challenges and Opportunities
  Thursday, October 17th, 10:15 – 11 AM, Learning Lounge 5
  Roy F. Chemaly, MD, MPH, FACP, FIDSA, The University of Texas MD Anderson Cancer Center, will give a presentation on the state of COVID-19, impediments to vaccine confidence, and opportunities for overcoming vaccination gaps.

• Facing the Challenges of RSV Season: Exploring the Efficiency and Efficacy of mRESVIA
  Friday, October 18, 11:15 – 12 PM, Learning Lounge 5
  Jeff A. Goad, PharmD, MPH, Aph, FISTM, FAPHA, FCSHP, FCPhA, CTH, Chapman University School of Pharmacy, will present data on Moderna’s vaccine for RSV disease, mRESVIA.

Visit Us at IDWeek 2024
If you’re planning to attend IDWeek 2024, we invite you to stop by our booth #517 to learn more about Moderna’s ongoing infectious disease research and to participate in immersive virtual reality experiences. At the medical booth, VR headsets will bring visitors into the world of mRNA manufacturing through a visit to pre-clinical lab spaces at Moderna’s manufacturing facility in Norwood, MA. A separate experience at the commercial booth guides visitors through the administration of mRESVIA’s pre-filled syringe.

Click here to register for IDWeek 2024 and learn more about Moderna’s presence.